Aptus Pharma IPO: SME Issue of 20 Lakh Shares Filed with BSE
By HDFC SKY | Published at: Jun 19, 2025 10:04 PM IST
Ahmedabad, June 19, 2025 – Gujarat-based Aptus Pharma Limited has filed its Draft Red Herring Prospectus (DRHP) with BSE for its upcoming IPO. The company plans to raise funds via a 100% fresh issue of up to 20 lakh equity shares, which will be listed on the BSE SME platform.
The issue does not include any offer for sale (OFS) component, and proceeds from the IPO will primarily support working capital and office infrastructure expansion.
IPO Snapshot
| Detail | Info |
|---|---|
| Issue Type | 100% Book-Built Fresh Issue |
| Issue Size | Up to 20,00,000 equity shares |
| Face Value | ₹10 per share |
| Listing Exchange | BSE SME |
| Price Band | To be announced |
| Lot Size | To be announced |
| BRLM | Interactive Financial Services Ltd |
| Registrar | Bigshare Services Pvt Ltd |
Company Overview
Founded in 2010 and converted into a public limited company in December 2024, Aptus Pharma is engaged in marketing and distribution of finished pharmaceutical formulations. The company does not own manufacturing facilities but relies on a contract manufacturing model, operating through seven manufacturers.
Its product portfolio spans various therapeutic categories, including:
- Anti-infectives
- Gastrointestinal and antacids
- Pain management
- Cardiovascular and anti-diabetics
- Neuro-psychiatric
- Nutritional and wellness supplements
These are marketed in multiple forms such as tablets, capsules, syrups, ointments, and injectables.
Financial Highlights
| Metric | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue from Operations | ₹1,389.73 L | ₹1,785.70 L | ₹2,455.77 L |
| Net Profit (PAT) | ₹19.43 L | ₹79.81 L | ₹309.96 L |
| EPS (₹) | 1.30 | 5.32 | 6.37 |
| Net Worth | ₹96.84 L | ₹176.65 L | ₹696.61 L |
| Total Borrowings | ₹221.18 L | ₹530.81 L | ₹1,035.68 L |
Use of Proceeds
The IPO proceeds will be directed towards:
- ₹173.46 lakh for capital expenditure on new office premises and storage infrastructure
- ₹1,038 lakh for working capital requirements
- Balance towards general corporate purposes
Promoter & Shareholding
The company is promoted by nine individuals, including Tejash Maheshchandra Hathi and Kapilbhai Hasmukhbhai Chandarana, who currently hold 100% of the pre-issue equity. No promoter shares are being sold in this issue.
What Investors Should Note
- Regional Concentration: Over 99% of FY25 revenue was generated from Gujarat.
- Contract-based Manufacturing: Entire production is outsourced, which may pose dependency risks.
- Working Capital Intensive: Significant growth in inventory and receivables has led to increased borrowing.
- Pending Trademarks: Several product brands are awaiting registration, including the corporate logo.
- IPO Fund Utilization: Not monitored by a third party; managed internally by the board.
Lead Managers & Registrar
- Book Running Lead Manager: Interactive Financial Services Limited
- Registrar to the Issue: Bigshare Services Pvt. Ltd.
Aptus Pharma’s IPO is expected to hit the markets in the coming weeks, subject to regulatory approvals and final RHP filing. The listing on the BSE SME platform aims to support the company’s next phase of growth in India’s expanding pharma market.
REF: https://www.bsesme.com/download/341484/SME_IPO InPrinciple/DRHP_Aptus__20250618225336.pdf
Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations
